Skip to content
Pediatrics in Maine: Fall 2021 Educational Series - 11-2
Atopic Dermatitis and Psoriasis
Presented by Peter A. Lio, MD
OK
1.
Will this activity enhance your competence or encourage you do anything differently after attending?
Yes
No
Optional - share an example:
2.
Will this activity influence your practice or patient outcomes?
Yes
No
Not sure
Comment:
3.
Was the presence of faculty conflict of interest or commercial support provided to the audience prior to the activity?
Yes
No
N/A
If yes, please specify:
4.
Please share your impressions of the speaker and presentation by rating the following:
Excellent
Good
Fair
Poor
Presentation Style
Excellent
Good
Fair
Poor
Knowledge of Material
Excellent
Good
Fair
Poor
Relevance of Topic
Excellent
Good
Fair
Poor
Connection with Audience
Excellent
Good
Fair
Poor
Comments:
5.
Are there any topics you would like to see covered in future webinars - and/or - would you like a follow up (perhaps to go more in-depth on one particular topic) to this session?
6.
What is your specialty?
Internist
Pediatrician
Dermatologist
Allergist
Other (please specify)
7.
How many years have you been in practice?
>21
11-20
1-10
<1
8.
How many patients with AD do you manage?
1-25
26-50
51-100
100+
I am not directly involved in patient care
9.
Please select the best option that best describes your practice setting:
Academic medical center
Community hospital or medical center
VA, DOD, or other government
Managed care
Research
Pharmaceutical industry
10.
How confident are you in the management of patients with AD in your practice? (Please answer before hearing the talk, and after hearing the talk.)
Very confident
Confident
Neutral
Slightly confident
Not confident
Before hearing this talk
Very confident
Confident
Neutral
Slightly confident
Not confident
After hearing this talk
Very confident
Confident
Neutral
Slightly confident
Not confident
11.
How would you classify the severity of AD in a patient with perceptible erythema, papulation, and lichenification with mild oozing?
Mild
Moderate
Severe
Before hearing this talk
Mild
Moderate
Severe
After hearing this talk
Mild
Moderate
Severe
12.
In addition to basic management comprising skin care and trigger avoidance, which of the following treatments would you prescribe for a patient with marked erythema, induration, and lichenification affecting 40% of the body, including the face and hands?
TCI
TCS
Crisaborole
Dupilumab
13.
What proportion of pediatric patients with moderate-to-severe AD do you think have been shown to achieve ≥75% improvement in lesion extent and severity when dupilumab is combined with TCS therapy?
30%
50%
70%
Before hearing this talk
30%
50%
70%
After hearing this talk
30%
50%
70%
14.
How do you think the rate of ISGA (Investigator’s Static Global Assessment) success in crisaborole-treated infants 3 to <24 months compare with that observed in previous studies of similarly treated patients ≥ 2 years?
Significantly greater
Significantly lower
Similar
Before hearing this talk
Significantly greater
Significantly lower
Similar
After hearing this talk
Significantly greater
Significantly lower
Similar
15.
Casey is a 7 year old with a 5 year history of mild-to-moderate AD. His parents report that, despite diligent treatment with a TCI, he frequently wakes up during the night due to itching, and that his behavior and academic performance at school are increasingly being affected. According to current best practice recommendations, what is the most appropriate next step for Casey?
A switch to a different topical anti-inflammatory
A step up in treatment to a biologic therapy or a systemic immunosuppressant
Referral to a specialist
16.
If you are seeking CME, please attest below:
I watched the entire hour long webinar.
Yes
No
17.
Provide your full name and credentials and your email address.
Name
Email Address
Current Progress,
0 of 17 answered
